Luhua (Michael) Wang, MD

Michael Wang, MD, discusses the safety and efficacy of KTE-X19 in relapsed/refractory mantle cell lymphoma.

Michael Wang, MD, discusses the safety and effectiveness of the autologous anti-CD19 CAR T-cell therapy KTE-X19 in patients with higher- versus lower-risk mantle cell lymphoma.

Michael Wang, MD, discusses correlative data from the phase 2 ZUMA-2 trial in mantle cell lymphoma (MCL).

Michael Wang, MD, discusses research trends in mantle cell lymphoma (MCL).

Michael Wang, MD, discusses the evolution of treatment in mantle cell lymphoma.

Michael Wang, MD, discusses the evolution of treatment in mantle cell lymphoma.

Michael Wang, MD, discusses the utility of CAR T-cell therapy in relapsed/refractory mantle cell lymphoma.

Michael Wang, MD, discusses the results of the phase 2 ZUMA-2 trial in relapsed/refractory mantle cell lymphoma.

Michael Wang, MD, discusses unique properties of the investigational CAR T-cell therapy KTE-X19 in relapsed/refractory mantle cell lymphoma.

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses ongoing research in mantle cell lymphoma (MCL).

Michael Wang, MD, discusses the safety profile of the CAR T-cell therapy KTE-X19 in patients with relapsed/refractory mantle cell lymphoma, according to results from the phase II ZUMA-2 trial.

Michael Wang, MD, discusses the results of the phase II ZUMA-2 trial in relapsed/refractory mantle cell lymphoma.

Michael Wang, MD, discusses the move towards precision medicine in mantle cell lymphoma.

Michael Wang, MD, discusses the benefit of BTK inhibitors in mantle cell lymphoma.

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the addition of acalabrutinib (Calquence) to bendamustine and rituximab (Rituxan; BR) in mantle cell lymphoma (MCL).

Michael Wang, MD, discusses the toxicity profiles of the BTK inhibitors ibrutinib, acalabrutinib, and zanubrutinib in mantle cell lymphoma.

Michael Wang, MD, discusses data from a phase I/II study looking at the use a triplet regimen of vorinostat, cladribine, and rituximab in patients with newly diagnosed mantle cell lymphoma.

Michael Wang, MD, discusses CAR T-cell therapy and triple-resistance in mantle cell lymphoma.

Michael Wang, MD, discusses resistance to CAR T-cell therapy and the next steps to overcoming this challenge in treatment for mantle cell lymphoma.

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the pace of progress in mantle cell lymphoma (MCL).

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses challenges in treating patients with relapsed/refractory mantle cell lymphoma (MCL).

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses emerging treatment strategies in mantle cell lymphoma.

Michael Wang, MD, a professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the promise of venetoclax in the treatment of patients with relapsed/refractory mantle cell lymphoma.

Michael Wang, MD, a professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses updated data with single-agent acalabrutinib in mantle cell lymphoma.

Michael Wang, MD, a professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses next steps for research with acalabrutinib in mantle cell lymphoma.

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the safety and efficacy of single-agent acalabrutinib in the treatment of mantle cell lymphoma.

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses new agents in the field of mantle cell lymphoma (MCL).

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the treatment of patients with relapsed/refractory mantle cell lymphoma.

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses how to manage adverse events related to BTK inhibitors in the treatment of mantle cell lymphoma.

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the ZUMA-2 trial in patients with relapsed/refractory mantle cell lymphoma.